Chester County News and Community Website
PHILADELPHIA, PA — Vittoria Biotherapeutics Inc. has announced its upcoming presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois. The trials-in-progress poster will spotlight …
Vittoria Biotherapeutics to Present VIPER-101 Phase 1 Trial at 2025 ASCO Annual Meeting Read More
WILMINGTON, DE — AstraZeneca has announced groundbreaking results from the BATURA Phase IIIb trial for AIRSUPRA (albuterol/budesonide), marking a significant advancement in asthma care. The anti-inflammatory rescue therapy demonstrated substantial …
AstraZeneca’s BATURA Trial Highlights Breakthrough Results for Asthma Treatment Read More
LANGHORNE, PA — Savara Inc. (Nasdaq: SVRA) unveiled significant findings from its Phase 3 IMPALA-2 clinical trial of molgramostim during two poster presentations at the ATS International Conference 2025. The …
Savara Showcases Promising Phase 3 Trial Data for Molgramostim at ATS 2025 Read More
RADNOR, PA — Mineralys Therapeutics, Inc. (Nasdaq: MLYS) has announced detailed results from its pivotal Phase 3 Launch-HTN trial, showcasing the efficacy and safety of lorundrostat for patients with uncontrolled …
Mineralys Therapeutics Reveals Promising Phase 3 Results for Hypertension Drug Lorundrostat Read More
WARRINGTON, PA — Windtree Therapeutics, Inc. (NasdaqCM: WINT) has unveiled new data on istaroxime, a treatment candidate for cardiogenic shock, at the European Society of Cardiology Heart Failure 2025 Conference …
Windtree Showcases Promising Istaroxime Data for Cardiogenic Shock at Major Conference Read More
WILMINGTON, DE — A new treatment option has emerged for patients battling advanced squamous cell carcinoma of the anal canal (SCAC). The U.S. Food and Drug Administration (FDA) has approved …
FDA Approves Zynyz for Advanced Anal Cancer, Offering New Hope for Patients Read More
PHILADELPHIA, PA — Century Therapeutics, Inc. (NASDAQ: IPSC) reported notable progress in Q1 2025, emphasizing advancements in its clinical and preclinical iPSC-derived cell therapy programs. Highlights include updates on the …
Century Therapeutics Reports Positive Q1 2025 Results and Advances in Cell Therapy Pipeline Read More
PHILADELPHIA, PA — Cabaletta Bio, Inc. (Nasdaq: CABA) has announced key updates on its RESET-Myositis trial and plans for the anticipated 2027 Biologics License Application (BLA) submission for rese-cel (resecabtagene …
Cabaletta Bio Updates Progress on RESET-Myositis Trial and Regulatory Milestones Read More
WARMINSTER, PA — Arbutus Biopharma Corporation (Nasdaq: ABUS), a key player in advancing treatments for chronic hepatitis B (cHBV), outlined its progress in Q1 2025, showcasing pivotal clinical milestones, financial …
Arbutus Biopharma Reports Q1 2025 Results, Clinical Developments, and Legal Progress Read More
MALVERN, PA — Annovis Bio Inc. (NYSE: ANVS) unveiled significant progress in its efforts to combat neurodegenerative diseases with updates on its pivotal Phase 3 clinical trial and solid financial …
Annovis Bio Advances Phase 3 Alzheimer’s Trial Amid Steady Financial Progress Read More